13G Filing: Partner Fund Management and Aerie Pharmaceuticals Inc (AERI)

Page 9 of 13

Page 9 of 13 – SEC Filing

CUSIP No. 00771V108 13G Page
9 of 13 Pages
Item 2(d) Title of Class of Securities
Common stock, $0.001 par value

 

Item 2(e) CUSIP Number
00771V108

 

Item 3 If this statement is filed pursuant to Rules 13d-1(b),
or 13d-2(b) or (c), check whether the person filing is a:
(a) ¨ Broker or dealer registered under Section 15 of the Exchange Act;
(b) ¨ Bank as defined in Section 3(a)(6) of the Exchange Act;
(c) ¨ Insurance company as defined in Section 3(a)(19) of the Exchange Act;
(d) ¨ Investment company registered under Section 8 of the Investment Company Act;
(e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
(g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
(i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
(k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as
a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

 

Follow Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Page 9 of 13